Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

Background: Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. Objectives: To estimate the clinical effectiveness of three interventions [everolimus (Afinitor®; Novartis International AG, Basel, Switzerland), lutetium-177 DO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage, Martin Hoyle
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2018-09-01
Colecção:Health Technology Assessment
Assuntos:
neuroendocrine tumours
nets
systematic review
economic model
cost-effectiveness
Acesso em linha:https://doi.org/10.3310/hta22490
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados